Vcanbio Cell & Gene Engineering Corp Book Value per Share
The Book Value per Share of Vcanbio Cell & Gene Engineering Corp (600645.SS) as of Oct 8, 2026 is 8.13 CNY. In the previous year, Book Value per Share was 7.88 CNY — a change of 3.10% (higher).
Get this data via API
Financial Data API
Book Value per Share
8.13CNY
YoY
3.10%
Last updated:
The Vcanbio Cell & Gene Engineering Corp Book Value per Share history
3 Years
10 Years
25 Years
Max
| YEAR | Book Value per Share | YoY |
|---|---|---|
| 8.13CNY | +3.10% | |
| 7.88CNY | -2.42% | |
| 8.08CNY | +3.61% | |
| 7.80CNY | +2.67% | |
| 7.59CNY | +1.42% | |
| 7.49CNY | +1.83% | |
| 7.35CNY | +20.96% | |
| 6.08CNY | +83.73% | |
| 3.31CNY | -4.96% | |
| 3.48CNY | +2.21% | |
| 3.41CNY | +50.46% | |
| 2.26CNY | — |
Vcanbio Cell & Gene Engineering Corp Stock analysis
Frequently Asked Questions about Vcanbio Cell & Gene Engineering Corp stock
Book Value per Share of Vcanbio Cell & Gene Engineering Corp is 8.13 CNY in 2025.
Book Value per Share of Vcanbio Cell & Gene Engineering Corp changed from 7.88 CNY to 8.13 CNY, representing a 3.10% change. The value is higher than the previous year.
On Eulerpool you can find the complete historical development of Book Value per Share Vcanbio Cell & Gene Engineering Corp since 2006 – with annual values, charts, and detailed analysis.
Book value per share represents the net asset value of the company per outstanding share. Comparing it to the stock price helps assess whether a stock is undervalued.
Balance Sheet — Vcanbio Cell & Gene Engineering Corp
All Key Metrics — Vcanbio Cell & Gene Engineering Corp
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth